de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, et al. - Using a multinational cohort including 1,103 Latin American multiple myeloma (MM) patients (median age, 61 years) who started first-line therapy (LOT1), researchers analyzed modern MM treatment practices in Latin America in this retrospective cohort study. Autologous stem cell transplantation (ASCT) was received by 33·9% of these patients. A reduction in the use of thalidomide-based treatment, from 66·7% to 42·6%, and chemotherapy from, 20·2% to 5·9%, was noted from 2008 to 2015 in the LOT1 setting, with a rise seen in bortezomib-based therapy or bortezomib + thalidomide use from 10·7% to 45·5%. A more common use of bortezomib-based therapy and bortezomib + thalidomide in ASCT patients and in private clinics was reported. Overall, areas of unmet therapeutic need in Latin America were unveiled by the observations that newer therapies had a slower uptake in public clinics and patients with relapsed MM had poor progression-free survival.